Hazard Ratios (95% Confidence Interval) for all-cause mortality in relation to change in body size by age group at baseline.

a<p>Estimates adjusted for sex, country of birth, quintile of socioeconomic status, body size at baseline, cumulative smoking status, and the following covariates measured at baseline and wave 2: physical activity, Mediterranean diet score and living alone.</p

Clinical details of the 19 <i>HOXB13</i> missense mutation G84E carriers (rs138213197), their male relatives and their mothers at baseline, sufficient to calculate the penetrance estimates.^*

*<p>B, brother; F, father; HB, half-brother; MU, maternal uncle; MGF, maternal grandfather; PU, paternal uncle; PGF, paternal grandfather; S, son.</p><p>Observation time began at date of birth and ended at the earliest of the following: date of diagnosis of prostate cancer, date at death, or 31 Dec 2011. Carrier status: + carrier, (+) obligate carrier, − non-carrier, ? unknown carrier status.</p

Hazard Ratios (95% Confidence Interval) for all-cause mortality in relation to change in body size.

a<p>Model 1: Estimates adjusted for sex and country of birth.</p>b<p>Model 2: Estimates adjusted for sex, country of birth, quintile of socioeconomic status, body size at baseline, cumulative smoking status, and the following covariates measured at baseline and wave 2: physical activity, Mediterranean diet score and living alone.</p

Hazard Ratios (95% Confidence Interval) for death due to obesity-related cancer or CVD in relation to change in body size.

a<p>Estimates adjusted for sex, country of birth, quintile of socioeconomic status, body size at baseline, cumulative smoking status, and the following covariates measured at baseline and wave 2: physical activity, Mediterranean diet score and living alone.</p>b<p>Obesity-related cancers include the following cancers: breast, colorectal, endometrial, oesophageal, kidney, pancreatic.</p

Flowchart of participants in the MCCS.

<p>Flowchart of participants in the MCCS.</p

Penetrance (age-specific cumulative risk) (solid line), and 95% confidence limits intervals (dashed lines), of prostate cancer for carriers of the HOXB13 missense mutation G84E (rs138213197) by selected years of birth.

<p>Penetrance (age-specific cumulative risk) (solid line), and 95% confidence limits intervals (dashed lines), of prostate cancer for carriers of the HOXB13 missense mutation G84E (rs138213197) by selected years of birth.</p

Penetrance (age-specific cumulative risk) and 95% confidence intervals of prostate cancer for carriers of the <i>HOXB13</i> missense mutation G84E (rs138213197) by selected years of birth.

<p>Penetrance (age-specific cumulative risk) and 95% confidence intervals of prostate cancer for carriers of the <i>HOXB13</i> missense mutation G84E (rs138213197) by selected years of birth.</p

Comparison of average blood and tumor-derived DNA methylation across a panel of tumor suppressor genes.

<p>Plotted β-values at CpG probes across defined genomic regions. Red line indicates average β-value for blood-derived DNA samples. Blue line indicates average β-values for tumor-derived DNA samples. * indicates significant statistical difference (p<0.01). Error bars are plotted Standard Error of Mean. Gene region schematics denote [CGI (CpG Island), TSS (Transcriptional Start Site)].</p

Characteristics of study participants.

<p>Data presented as mean (SD) or number (%)</p><p>Characteristics of study participants.</p

Sample tumor DNA methylation at the <i>MLH1</i> promoter region.

<p>Plotted β-values for each sample at each CpG probe across <i>MLH1</i> (chr3:37,033,277 –chr3:37,082,650). Solid black line indicates average β-values for blood-derived DNA. Dotted black line indicates average β-values for tumor-derived DNA. Schematic of four <i>MLH1</i> promoter regions previously defined by Deng <i>et al</i>, base pair number is in relation to the start codon (ATG) Regions. * highlights tumor-derived DNA samples showing increased <i>MLH1</i> methylation. Gene region schematic denotes [CGI (CpG Island), TSS (Transcriptional Start Site)]</p